Mondi, Annalisa
 Distribuzione geografica
Continente #
EU - Europa 1.414
NA - Nord America 1.025
AS - Asia 331
AF - Africa 9
SA - Sud America 9
Totale 2.788
Nazione #
US - Stati Uniti d'America 1.008
DE - Germania 388
PL - Polonia 311
FR - Francia 205
SE - Svezia 166
CN - Cina 138
IT - Italia 123
SG - Singapore 96
UA - Ucraina 87
GB - Regno Unito 42
IN - India 42
IE - Irlanda 40
FI - Finlandia 26
ID - Indonesia 23
TR - Turchia 16
CA - Canada 15
RU - Federazione Russa 9
BE - Belgio 8
CM - Camerun 8
IR - Iran 7
BR - Brasile 6
HK - Hong Kong 3
DK - Danimarca 2
ES - Italia 2
KR - Corea 2
LT - Lituania 2
PH - Filippine 2
AE - Emirati Arabi Uniti 1
AR - Argentina 1
AT - Austria 1
CL - Cile 1
EC - Ecuador 1
LU - Lussemburgo 1
MM - Myanmar 1
MX - Messico 1
NG - Nigeria 1
NL - Olanda 1
PA - Panama 1
Totale 2.788
Città #
Kraków 310
Chandler 214
Jacksonville 82
Ashburn 70
Singapore 67
New York 51
Dublin 40
San Mateo 40
Ann Arbor 39
Nanjing 35
Milan 34
Redmond 33
Dearborn 30
Houston 29
Nürnberg 27
Cattolica 26
Jakarta 23
Wilmington 23
Lawrence 22
Redwood City 20
Lancaster 19
Boston 18
Woodbridge 17
Izmir 16
Nanchang 16
Ottawa 13
Los Angeles 10
Changsha 9
Brussels 8
Hebei 8
Leawood 8
Rome 8
Fairfield 7
Falls Church 7
Mountain View 7
Shenyang 7
Beijing 6
Boardman 6
Chicago 6
Fremont 6
Norwalk 6
Augusta 5
Guangzhou 5
Jinan 5
Kunming 5
Moscow 5
Munich 5
Paris 5
Seattle 5
Tianjin 5
Bari 4
Simi Valley 4
University Park 4
Washington 4
Auburn Hills 3
Busto Arsizio 3
Cambridge 3
Clearwater 3
Hefei 3
Kish 3
London 3
Marseille 3
Modena 3
Pune 3
Shanghai 3
Bologna 2
Bremen 2
Faenza 2
Frankfurt am Main 2
Fuzhou 2
Hangzhou 2
Helsinki 2
Henderson 2
Hong Kong 2
San Jose 2
Toronto 2
Amsterdam 1
Andover 1
Ardabil 1
Bangalore 1
Cameri 1
Cebu City 1
Central District 1
Changchun 1
Cheboksary 1
Chengdu 1
Clifton 1
Criciúma 1
Dallas 1
Downers Grove 1
Dubai 1
Edinburgh 1
Forest City 1
Guidonia 1
Jiaxing 1
Kashan 1
Landshut 1
Langfang 1
Lanzhou 1
Latina 1
Totale 1.563
Nome #
Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study) 211
Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility 176
Prevalence of osteoporosis and predictors of low BMD in a cohort of HIV-1-infected patients in Rome: features of a population at high risk 170
Liver fibrosis is associated with cognitive impairment in HIV-positive patients 165
Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre 160
Evaluation of emotion processing in HIV-infected patients and correlation with cognitive performance 151
Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study) 151
Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA 136
Neuropsychological screening tools in Italian HIV+ patients: a comparison of Montreal Cognitive Assessment (MoCA) and Mini Mental State Examination (MMSE) 134
Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naïve or switching for simplification HIV-infected patients 133
Ophthalmic artery resistance index IS increased in HIV-Infected patients and is influenced by protease inhibitors exposure 123
Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial 120
Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy 106
Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study 105
Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study 102
Reduced risk of Efavirenz Discontinuation in Naïve Patients Starting First-Line Antiretroviral Therapy with Single Tablet versus dual Tablet Regimen 100
Increased ophthalmic artery resistance index is associated with cognitive impairment in HIV-infected patients. 96
Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients 92
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M) 91
Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons 87
Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA 85
Risk of chronic kidney disease among patients developing mild renal impairment during tenofovir-containing antiretroviral treatment 69
Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients 66
Totale 2.829
Categoria #
all - tutte 8.901
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.901


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020231 0 0 0 0 46 31 19 30 26 22 37 20
2020/2021190 10 24 4 17 27 15 12 5 35 4 32 5
2021/2022258 22 17 9 28 12 18 4 38 12 26 30 42
2022/2023491 75 87 32 74 44 57 7 43 62 0 5 5
2023/2024264 12 77 6 26 15 66 11 0 4 4 30 13
2024/2025140 7 16 26 24 67 0 0 0 0 0 0 0
Totale 2.829